Physiological upper limits of ventricular cavity size in highly trained adolescent athletes

J Makan, S Sharma, S Firoozi, G Whyte, P G Jackson, W J McKenna

Objectives: To define physiological upper limits of left ventricular (LV) cavity size in trained adolescent athletes. 

Design: Cross sectional echocardiographic study. 

Setting: British national sports training grounds and Olympic Medical Institute. 

Subjects: 900 elite adolescent athletes (77% boys) aged 15.7 (1.2) years participating in ball, racket, and endurance sports and 250 healthy controls matched for age, sex, and size. 

Main outcomes measures: LV end diastolic cavity size. 

Results: Compared with controls, athletes had a larger LV cavity (50.8 (3.7) vs 47.9 (3.5) mm), a difference of 6%. The LV cavity was > 54 mm in 18% athletes, whereas none of the controls had an LV cavity > 54 mm. The LV cavity exceeded predicted sizes in 117 (13%) athletes. Among the athletes with LV dilatation, 78% were boys, LV size ranged from 52–60 mm, and left atrial diameter and LV wall thickness were enlarged. Systolic and diastolic function were normal. None of the athletes in the study had an LV cavity size > 60 mm. LV cavity size correlated with age, sex, heart rate, and body surface area. 

Conclusion: Highly trained junior athletes usually have only modest increases in LV cavity size. A proportion of trained adolescent athletes have LV cavity size exceeding predicted values but, in absolute terms, LV cavity rarely exceeds 60 mm as in patients with dilated cardiomyopathy. In highly trained adolescent athletes with an LV cavity size > 60 mm and any impairment of systolic or diastolic function, the diagnosis of dilated cardiomyopathy should be considered. 

METHODS 

Athletes 

Between August 1996 and November 2003, 900 post-pubertal adolescent elite athletes aged 15.7 (1.2) years (range 14–18 years) underwent two dimensional echocardiography during the competitive season. Six hundred and sixty four (74%) were boys; 882 (98%) were white. Body surface area (BSA) among the athletes was 1.74 (0.16) m² (range 1.09–2.24 m²). 

Written consent for cardiovascular evaluation was obtained from participants aged ≥16 years and from a parent or guardian for those < 16 years old. 

The study group was predominantly made up of 10 sporting disciplines: boxing, cycling, hockey, karate, rowing, rugby, soccer, swimming, tennis, and triathlon. Soccer and tennis were the most commonly studied sports and between them accounted for 414 (46%) athletes (table 1). Tennis players were recruited from the British Lawn Tennis Association, soccer players from youth teams at clubs in the British Premier Soccer League, boxers from prominent amateur boxing association clubs, rugby players from British Rugby League clubs, cyclists from large county cycling squads, triathletes from top 10 finishers at the national UK championships, and rowers, swimmers, and hockey and karate players from British junior national teams. An additional 18 (2%) had participated at the national level in squash, fencing, and track and field events. All athletes had competed at the regional level for a mean (SD) of 4.3 (1.5) years (range 1–10 years) and 50% were competing at the national level at time of this study. The
number of hours of intensive training averaged 10.6 (3.5) hours/week (range 6–30 hours). No athlete had symptoms of underlying cardiovascular disease or a family history of premature (aged < 50 years) sudden death from heart disease, and none had a blood pressure exceeding 130 mm Hg systolic or 85 mm Hg diastolic.

Controls
The control population comprised 250 healthy adolescent volunteers who were students at two large secondary education boarding schools. All selected participants led a relatively sedentary lifestyle, defined as < 2 hours of organised physical activity a week. Controls were well matched to the trained athletes with regard to age, sex, and BSA (15.5 (1.2) years (range 14–18 years), 71% boys, 1.71 (0.4) m² (range 1.17–2.24 m²), respectively, not significant).

Echocardiography
Two dimensional echocardiograms were recorded with a computed sonograph (128XP/10c, Acuson, San Jose, California, USA) with a 3 MHz transducer. Images of the heart were obtained in the standard parasternal long axis, short axis, and apical four chamber planes. The LV wall thickness was measured from the short axis views of the anterior septum and LV posterior wall in end diastole at the mitral valve and papillary muscle levels. LV end diastolic and end systolic diameters were measured from short axis views at the tips of the mitral valve. All measurements were made on line by two authors (SS and SF) with the aid of a calibration scale provided by the machine. M mode echocardiograms were derived from two dimensional images in the parasternal long axis to assist in the measurement of the left atrial and aortic root diameters according to standards set by the American Society of Echocardiography. The LV shortening fraction was calculated as an index of systolic function. Pulsed Doppler images were recorded at the level of the mitral valve annulus as described previously to provide an index of diastolic function. Continuous wave Doppler images were recorded across the LV inflow and outflow tract. LV mass was calculated from the LV cavity size and wall thickness in end diastole by the formula by Devereux. Predicted upper limits for normal LV cavity size were derived from the control group. The predicted upper limits were defined as two standard deviations from the mean (table 2).

In accordance with usual clinical practice we relied on absolute LV end diastolic cavity sizes; however, for selective comparisons of sex, age, and sporting disciplines, measurements were corrected for differences in BSA.

Statistical analysis
Statistical analyses were performed by unpaired Student’s t test, analysis of variance, χ² test, correlation coefficient, and linear regression where appropriate. Significance was defined by p < 0.05.

RESULTS LV cavity size and LV function in athletes versus controls
Athletes had a significantly larger LV cavity (fig 1), LV wall thickness, and left atrial diameter than the control group (table 3). The percentage difference in mean absolute LV

Table 2 Predicted upper levels of left ventricular (LV) cavity size in healthy adolescents aged 14–18 years based on 250 controls

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Boys</th>
<th>Girls</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEDD (mm)</td>
<td>Predicted upper limit (2SD)</td>
<td>LVEDD (mm)</td>
</tr>
<tr>
<td>14</td>
<td>46.1 (4.0)</td>
<td>54.1</td>
</tr>
<tr>
<td>15</td>
<td>49.8 (2.2)</td>
<td>54.2</td>
</tr>
<tr>
<td>16</td>
<td>50.4 (2.6)</td>
<td>55.7</td>
</tr>
<tr>
<td>17</td>
<td>50.3 (2.2)</td>
<td>54.7</td>
</tr>
<tr>
<td>18</td>
<td>49.0 (3.9)</td>
<td>56.7</td>
</tr>
</tbody>
</table>

Values are mean (SD). LVEDD, left ventricular end diastolic diameter.

Figure 1 Distribution of left ventricular (LV) cavity size in 900 junior elite athletes (open bars) and 250 healthy controls (solid bars).
Ventricular cavity dilatation in junior athletes

The vast majority of athletes had an absolute LV cavity size falling within normal values derived from controls (table 4). However, 117 (13%) athletes had a LV cavity exceeding the predicted upper limits of normal. The LV cavity in these 117 athletes ranged from 52–60 mm.

Demographics

Of these 117 athletes with an enlarged LV cavity, 91 (78%) were boys. Athletes in this group were slightly older (15.7 (1.2) v 15.6 (1.3) years, p < 0.05) and had a greater BSA (1.84 (0.18) v 1.73 (0.16) m², p < 0.05) than athletes with a normal LV cavity. After correction for BSA, the mean LV cavity in the 117 athletes remained greater than that in athletes with a normal LV cavity (30.7 (2.5) v 29.1 (2.2) mm/m², p < 0.05). Athletes participating in rowing, swimming, soccer, tennis, triathlon, athletics, badminton, and speed skating were represented in this group. A significant proportion of rowers and cyclists (43% and 41%, respectively) had an enlarged LV cavity.

Echocardiographic parameters

Athletes with an enlarged LV cavity also had a larger mean LV wall thickness (10.1 (1.3) v 9.5 (1.3) mm, p < 0.05) and mean left atrial diameter (34.8 (4.0) v 32.4 (4.8) mm, p < 0.05) than did athletes with a normal sized LV cavity. The mean shortening fraction in athletes with an enlarged LV cavity was 37 (4)% (range 32–43%). Athletes with an enlarged LV cavity had normal indices of systolic and diastolic function that did not differ from those of athletes with a normal LV cavity.

DISCUSSION

Echocardiographic studies of adult athletes have defined upper limits of physiological LV cavity enlargement; however, data regarding LV cavity size in younger athletes are limited. Apart from being of physiological interest, information regarding the upper limits of LV cavity size in elite adolescent athletes may be useful in enabling the differentiation between physiological LV cavity enlargement (part of athlete’s heart) and DCM. The differentiation is particularly important in instances where indices of systolic function are at the lower limit of the normally acceptable range in an athlete in question or when an athlete is experiencing symptoms that may be consistent with an underlying cardiac problem. Our study of 900 adolescents aimed at defining upper limits of physiological LV cavity enlargement in highly trained adolescent athletes aged 14–18 years.
Athletes with enlarged LV cavity

Our athletes had modest increases in LV cavity size compared with non-athletes. Although the majority of athletes in the study had a normal LV cavity (usually <54 mm), an important minority 117 (13%) had an LV cavity exceeding predicted limits. The LV cavity did not exceed 60 mm in any athlete irrespective of age, size, sex, sporting discipline, and duration of participation in sport or athletic achievement (in terms of representation at the national level). Therefore, extreme forms of LV remodelling resulting in LV >60 mm in junior athletes should raise the possibility of underlying DCM in athletes with diminished indices of systolic function on the resting echocardiogram. Sex differences may prove pertinent in the differentiation between physiological and pathological LV enlargement. In our study most athletes with an enlarged LV cavity were boys. Although 12% of girls had an enlarged LV cavity, none had an LV >55 mm. Consequently, an LV >55 mm in a female junior athlete should raise the suspicion of DCM, particularly if systolic or diastolic parameters are abnormal.

Our 117 athletes with an enlarged LV cavity had several echocardiographic features permitting differentiation from DCM. All 117 athletes had normal indices of systolic and diastolic function. In contrast most young patients with DCM have impaired systolic or diastolic LV dysfunction. Our 117 athletes with increased LV cavity size had increased LV wall thickness and left atrial diameter, which may accompany both physiological and pathological LV enlargement. Normal systolic function in our athletes suggested that the increased LV wall thickness indicated physiological LV hypertrophy rather than the compensatory hypertrophy seen in DCM. Normal mitral inflow velocities indicated that increased left atrial diameter was also part of general physiological cardiac enlargement rather than diastolic dysfunction secondary to DCM.

Determinants of LV cavity size in athletes

The study relied on absolute cardiac dimensions to place the results in context with usual clinical practice. Our multivariate analysis showed that BSA, sex, and heart rate were independent determinants of LV cavity size. Individual cardiac dimensions in athletes varied within the same sport even after allowing for these determinants indicating that some other factors, possibly genetic, may also be important in determining the cardiac adaptation to exercise.16 17

The duration of participation in competition and number of hours of training a week did not correlate with cavity dimensions. A possible explanation for this is that neither is a reliable index of intensity of training. A more accurate way may have been to objectively assess each athlete’s training schedule. An alternative explanation may be that cavity dimensions are genetically determined and that people with larger cavity size are naturally selected to excel in sport. However, longitudinal studies of athletes have shown that cavity dimensions do increase with training and regress with detraining.18 20 Furthermore, studies of pre-pubertal children have not found any difference in cavity dimensions between athletes and controls to suggest natural selection of people with large hearts.21 22

Difference in LV cavity size between adult and adolescent athletes

Adolescent athletes were similar to adult athletes in many respects. For example, LV cavity was largest in boys with large BSAs. As with adult athletes, adolescent athletes participating in endurance events such as rowing and cycling usually had LV cavity sizes exceeding predicted limits. However, the difference in LV size between athletes and non-athletes was considerably smaller among adolescent athletes than observed among adult athletes. Also, whereas 45% adult athletes have an LV cavity ≥55 mm and 14% have an LV cavity ≥60 mm,2 of adolescent athletes had an LV cavity ≥55 mm and only one (0.1%) athlete had an LV cavity ≥60 mm. The largest LV cavities in adult males and female athletes were 70 mm and 66 mm, respectively, but none of our male athletes had an LV cavity >60 mm and none of the female athletes had an LV cavity >55 mm. These fundamental differences in LV cavity size between adult and adolescent athletes probably reflect the relative lack of physical maturity and fewer cumulative hours of training among adolescent athletes. These differences underscore the importance of using separate cut off values for adolescent athletes when differentiating between physiological LV cavity enlargement and DCM.

This study was limited by the fact that only athletes participating in popular sports in the UK were evaluated, whereas common US sports such as basketball and American football were not represented. Similarly, athletes performing predominantly isometric training such as power lifters were not studied because of the difficulty obtaining large numbers of junior athletes participating at the national level. Furthermore, almost all (98%) of our study population was white and therefore the effects of racial variation could not be studied. Despite these limitations, this study provides valuable information regarding the upper limit of LV cavity size in the highly trained junior athlete and will prove clinically

Table 4 Comparison of demographic and echocardiographic variables between athletes with enlarged LV cavity and athletes with LV cavity size within predicted limits

<table>
<thead>
<tr>
<th>Parameter</th>
<th>LV cavity size within normal limits</th>
<th>LV cavity size exceeding predicted upper limits</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>783</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>15.6 (1.3)</td>
<td>15.7 (1.2)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>171.0 (8.5)</td>
<td>175.4 (9.3)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>62.5 (2.2)</td>
<td>68.8 (10.6)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>1.73 (0.16)</td>
<td>1.84 (0.18)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>53.7 (3.2)</td>
<td>45.7 (3.8)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Training intensity (hours/week)</td>
<td>4.32 (1.45)</td>
<td>4.44 (1.85)</td>
<td>NS</td>
</tr>
<tr>
<td>Left atrial diameter (mm)</td>
<td>32.4 (4.8)</td>
<td>34.8 (4.0)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>50.0 (3.3)</td>
<td>55.8 (2.0)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>MLWWT (mm)</td>
<td>9.5 (1.3)</td>
<td>10.1 (1.3)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Aortic root diameter (mm)</td>
<td>28.6 (3.5)</td>
<td>30.0 (3.4)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>LV mass (g)</td>
<td>190.3 (60.1)</td>
<td>262.9 (66.1)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>E wave (m/s)</td>
<td>0.86 (0.15)</td>
<td>0.91 (0.17)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>A wave (m/s)</td>
<td>0.41 (0.11)</td>
<td>0.43 (0.11)</td>
<td>NS</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.25 (0.72)</td>
<td>2.19 (0.63)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are means [SD].
Three dimensional transthoracic echocardiography images of tricuspid stenosis

A 56 year old man was admitted for evaluation of exertional dyspnoea. His medical history was significant for rheumatic mitral and aortic valve disease. A transthoracic three dimensional (3D) echocardiography examination was performed using a Philips Sonos 7500 (Philips Medical Systems, Eindhoven, the Netherlands) and a new 4 MHz, 4X matrix transducer capable of providing real time two dimensional (2D) and live 3D transthoracic images. Pyramidal shaped full volume 3D images were acquired with ECG gating by asking the patient to hold his breath for a few seconds. The system permits cropping of 3D images in three different orthogonal axes (lateral, elevational, and depth). The image was cropped using an elevational cutting plane to obtain the profile of the tricuspid valve area viewed from the apex perspective. Three dimensional images were then digitally stored on optical disk and transferred into a dedicated computer (Tom-TEC, Echo-View) for measurements. A valve area of 1.4 cm² was measured.

Tricuspid stenosis is a rare clinical condition with rheumatic disease accounting for about 90% of all cases. Two dimensional echocardiography permits definitive diagnosis of tricuspid stenosis showing thickening and shortening of the valve leaflets. Nevertheless, unlike evaluation of mitral stenosis, short axis 2D imaging of the valve orifice is rarely feasible. In this patient, an image of tricuspid valve area was easily obtained using 3D transthoracic echocardiography. To our knowledge these images have not been reported previously.

F Faletra
U La Marchesina
R Bragato
F De Chiara
francesco.faletra@humanitas.it

www.heartjnl.com
Physiological upper limits of ventricular cavity size in highly trained adolescent athletes

J Makan, S Sharma, S Firoozi, G Whyte, P G Jackson and W J McKenna

*Heart* 2005 91: 495-499
doi: 10.1136/hrt.2004.035121

Updated information and services can be found at:
http://heart.bmj.com/content/91/4/495

These include:

**References**

This article cites 20 articles, 11 of which you can access for free at:
http://heart.bmj.com/content/91/4/495#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Hypertension (3006)
- Dilated cardiomyopathy (292)
- Drugs: cardiovascular system (8842)
- Heart failure (565)
- Clinical diagnostic tests (4779)
- Echocardiography (2127)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/